# AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

> **NCT03718143** · PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 6 (actual)

## Conditions studied

- Myelofibroses
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Combination AZD1775 with AraC
- **DRUG:** AZD1775 only

## Key facts

- **NCT ID:** NCT03718143
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-08
- **Primary completion:** 2019-09-27
- **Final completion:** 2019-09-27
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Safety concerns
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03718143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03718143, "AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03718143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*